La catena delle opzioni mostra i dati chiave delle opzioni azionarie di KalVista Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per KalVista Pharma..

KalVista Pharma (NASDAQ:KALV) Azioni, Catena delle Opzioni

KALVISTA PHARMACEUTICALS INC

KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals Inc

Perma-Pipe International Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPIH#NASDAQ">PPIH</a>) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there.
The project will be for USD $2.4 million and will utilize Perma-Pipe's fabrication capabilities and the XTRU-THERM&#xAE; insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing.
 &nbsp;

News

PPIH

Perma-Pipe Wins $2.4M Qatar Contract, Expanding Presence With Fabrication & XTRU-THERM Technology

Amazon Aurora DSQL effortlessly scales to meet any workload demand and provides 99.999% multi-Region availability, strong consistency, and PostgreSQL compatibility, all with zero infrastructure management
Amazon Web Services, Inc. (AWS), an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Famazon.com%2F&amp;esheet=54260950&amp;newsitemid=20250527678337&amp;lan=en-US&amp;anchor=Amazon.com&amp;index=1&amp;md5=5607155270dd01b2ebdfba5f041fec7b">Amazon.com</a>, Inc. company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), today announced the general availability of Amazon Aurora DSQL, a serverless, distributed SQL database that enables customers to easily create databases to build applications with the highest availability, multi-Region strong consistency, PostgreSQL compatibility, and read and write speeds up to 4x faster than other popular distributed SQL databases. Until now, customers building globally distributed applications faced difficult trade-offs when selecting a database: Existing solutions offered either low latency without strong consistency, or strong consistency with high latency, but never both low latency and strong consistency in a highly available SQL database. With Aurora DSQL, customers no longer need to make these trade-offs, enabling them to build highly available applications at any scale without the operational burden of patching, upgrades, and maintenance downtime.
<ul>
<li>Amazon Aurora DSQL is now generally available in eight AWS Regions, with availability in additional Regions coming soon.</li>
<li>Customers and Partners including ADP, Cintra, Caylent, DeNA, Robinhood, and more are using Amazon Aurora DSQL to build highly resilient applications that meet the most stringent business continuity requirements.</li>
</ul>

AMZN

AWS Announces General Availability Of Amazon Aurora DSQL: Serverless, Distributed SQL Database Offering 99.999% Multi-Region Availability, Strong Consistency, PostgreSQL Compatibility, And 4x Faster Performance Without Infrastructure Management

Private equity firms TPG and Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) recently bid to acquire Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), valuing the U.S. medical technology company at over $16 billion.
Hologic is an American medical technology company primarily focused on women&#8217;s health. It sells medical devices for diagnostics, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">surgery, and imaging</a>.
While Hologic rejected the initial nonbinding offer, citing sources, the Financial Times writes that the negotiations could resume.
Benzinga reached out to Hologic for comments.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/01/43065688/fda-warns-hologic-over-biozorb-manufacturing-violations" target="_blank" rel="noreferrer noopener">FDA Warns Hologic Over BioZorb Manufacturing Violations</a>
The proposed buyout valued Hologic between $16.3 billion and $16.7 billion, including debt, and would have priced shares at $70 to $72—well above the company&#8217;s closing price of $54.28 on Friday.
The FT report adds that if successful, the deal would have ranked among the largest leveraged buyouts of the year.
Despite the generous premium, Hologic declined the approach. Its stock has dropped about 24% this year, weighed down by U.S. tariffs and softening demand.
Hologic reported adjusted earnings of $1.03 per share for the second quarter of 2025, the same as last year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $1.02</a>. Sales decreased 1.2% year over year to $1.05 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/05/b45149552/hologic-announces-financial-results-for-second-quarter-of-fiscal-2025" target="_blank" rel="noreferrer noopener">consensus of $1 billion</a>.
Hologic lowered fiscal 2025 adjusted earnings per share guidance from $4.25-4.35 to $4.15-4.25 compared to consensus of $4.26, based on tariffs and geopolitical conditions.
The company reaffirmed sales guidance of $4.05 billion-$4.10 billion compared to the consensus of $4.08 billion.
Hologic expects third-quarter adjusted earnings of $1.04-1.07 per share versus consensus of $1.10 and sales of $1 billion-1.01 billion compared to the consensus of $1.03 billion.
The FT report <a target="_blank" href="https://www.ft.com/content/f4d12c75-1a54-4d8c-8aa6-f863cbdc4aab" rel="noreferrer noopener">noted</a> that CEO MacMillan acknowledged in the company&#8217;s recent quarterly earnings call that the business had endured &#8220;a tumultuous few months from a macroeconomic and policy perspective.&#8221; Still, it emphasized that the firm is making progress.
Hologic has long been viewed as a possible takeover target. Activist investor Carl Icahn acquired a 12.5% stake in 2013, prompting the company to adopt a poison pill strategy. Icahn later secured two board seats and influenced leadership changes, including Steve MacMillan&#8217;s appointment as CEO.
Price Action: HOLX stock is up 15.1% at $62.48 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" target="_blank" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>

Large Cap

Health Care

Rumors

Movers

Media

Trading Ideas

General

HOLX

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Cryptocurrency markets are up on Tuesday amid reports of Trump Media Group pursuing a <a href="https://www.benzinga.com/markets/25/05/45611864/trump-media-group-reportedly-plans-to-raise-3-billion-to-buy-cryptocurrencies-borrowing-a-page-from-mstr-playbook-says-peter-schiff">Bitcoin acquisition strategy</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$109,710</td>
<td>+0.6%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,681</td>
<td>+5.7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$178.75</td>
<td>+2.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.34</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2275</td>
<td>+1.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001451</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 32% and daily active addresses growing by 21%. </li>
<li>Coinglass data reports 161,179 traders were liquidated in the past 24 hours for $563.57 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45615233/michael-saylor-calls-proof-of-reserves-a-crypto-parlor-trick-but-binances-ex-ceo-cz-isnt-having-it-he-probably-sold-bitcoins">Michael Saylor Calls Proof Of Reserves A &#8216;Crypto Parlor Trick&#8217;, But Binance&#8217;s Ex-CEO CZ Isn&#8217;t Having It: &#8216;He Probably Sold Bitcoins&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45616666/dogecoin-shiba-inu-and-other-meme-coins-are-entry-points-to-crypto-ecosystem-report">Dogecoin, Shiba Inu And Other Meme Coins Are Entry Points To Crypto Ecosystem: Report</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45614311/fraudster-sam-bankman-fried-set-to-leave-prison-four-years-early-as-good-conduct-credits-t">Fraudster Sam Bankman-Fried Set To Leave Prison Four Years Early As &#8216;Good Conduct&#8217; Credits Trim His 25-Year Sentence</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45624852/dogecoins-chart-screams-caution-as-bulls-get-rejected-again">Dogecoin&#8217;s Chart Screams Caution As Bulls Get Rejected Again</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Trader Notes: Prominent trader Pentoshi remains bullish on both ETH and SOL, <a href="https://x.com/Pentosh1/status/1927441348669399229">saying</a> Ethereum &#8220;still looks good&#8221; and Solana <a href="https://x.com/Pentosh1/status/1927440697151332752">is</a> &#8220;knocking at resistance.&#8221;
Trader Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1927434574369321401">warns</a> of trying to short Bitcoin, calling it &#8220;the greatest asset on the planet.&#8221;
The Flow Horse <a href="https://x.com/TheFlowHorse/status/1927430406707490895">points out</a> Bitcoin&#8217;s divergence from the S&amp;P 500, which is up 2% on the day, musing whether the apex crypto is lagging or &#8220;congested.&#8221; 
Former Fox Business reporter Eleanor Terrett <a href="https://x.com/EleanorTerrett/status/1927418995549880766">flagged</a> Wyoming&#8217;s GOP senator Cynthis Lummis&#8216;s panel discussion at the Bitcoin conference, where the latter hinted at the U.S. government withholding information about the exact amount of Bitcoin it holds in its reserves.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45626262/trump-meme-coin-dinner-turned-into-high-net-worth-crypto-networking-trump-was-there-for-20">TRUMP Meme Coin Dinner Turned Into High-Net-Worth Crypto Networking: &#8216;Trump Was There For 20 Minutes&#8217;</a></li>
</ul>
Image: Shutterstock

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Up As Trump Media Group Announces Bitcoin Acquisition Plan

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lymphopoietin) and IL-13</a>.
Teva has an exclusive license to develop BD9 for TH2-driven inflammatory diseases such as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45615937/teva-and-biolojic-design-initiate-ind-enabling-studies-of-bd9-a-multibody-designed-to-explore-the-" rel="noreferrer noopener">atopic dermatitis and asthma</a>.&nbsp;
By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum</a>
The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option. It will pave the way for clinical trials and ultimately bring hope to underserved patient populations.
Under the terms of their agreement, Teva is developing BD9 worldwide.
In exchange, Biolojic is eligible to receive milestone payments based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones, including the initiation of IND-enabling studies.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In January, The U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of anaphylaxis, a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174108/fda-warns-of-severe-allergic-reaction-risk-with-tevas-multiple-sclerosis-drug" rel="noreferrer noopener">forms of multiple sclerosis (MS)</a>.
Glatiramer acetate, sold under the brand name Copaxone by&nbsp;Teva and as generics like Glatopa, is an injectable medication designed to reduce the frequency of MS relapses.
In February, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with&nbsp;Teva Pharmaceuticals.
The settlement resolves all patent litigation related to Axsome's Auvelity (dextromethorphan HBr –&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Price Action: TEVA stock is up 6.01% at $17.98 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

Biotech

Contracts

ALVO

AXSM

TEVA

Why Is Teva Stock Trading Higher On Tuesday?

<a href="https://www.bloomberg.com/news/articles/2025-05-27/apple-to-debut-dedicated-gaming-app-within-days-of-switch-2-s-arrival?srnd=phx-technology" title="https://www.bloomberg.com/news/articles/2025-05-27/apple-to-debut-dedicated-gaming-app-within-days-of-switch-2-s-arrival?srnd=phx-technology">https://www.bloomberg.com/news/articles/2025-05-27/apple-to-debut-dedicated-gaming-app-within-days-of-switch-2-s-arrival?srnd=phx-technology</a>

AAPL

'Apple to Debut Dedicated Gaming App Within Days of Switch 2's Arrival' - Bloomberg News

HC Wainwright upgraded Kyverna Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>), citing three upcoming data sets <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">through mid-2025</a>.
In its first quarter 2025 earnings released, the company highlighted:
<ul class="wp-block-list">
<li>Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). 
<ul class="wp-block-list">
<li>The trial is on track for topline data and a biologics license application (BLA) filing is now anticipated in the <a href="https://www.benzinga.com/pressreleases/25/05/n45390028/kyverna-therapeutics-provides-business-update-and-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">first half of 2026</a>.</li>
</ul>
</li>
<li>Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA). Phase 2 MG data is anticipated in the second half of 2025.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698463/cartesian-therapeutics-reports-strong-12-month-data-for-lead-cell-therapy-in-myasthenia-gravis-patients" rel="noreferrer noopener">Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients</a>
Kyverna reported&nbsp;$242.6 million&nbsp;in cash, cash equivalents, and available-for-sale marketable securities as of&nbsp;March 31, 2025. The company expects this to provide a cash runway into 2027.
&#8220;Ahead of three catalysts, we think the risk-reward profile attractive, particularly given a deeply negative enterprise value,&#8221; says HC Wainwright analyst Mitchell S. Kapoor.
Kapoor wrote on Tuesday, &#8220;We note that this cash position enables investors to own KYTX effectively as a call option that could provide meaningful upside if any of these catalysts were to be positive. In the same vein, since the stock currently trades at such a massive discount to cash, we believe there is considerable mitigation baked in against downside risk.&#8221;
HC Wainwright sees near-term potential in the MG opportunity, mainly due to encouraging early results from three compassionate-use patients. Additionally, the analyst says that an upcoming update on how long the treatment lasts in these patients could be an even stronger catalyst, possibly showing durability comparable to rivals like Cartesian Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>).
HC Wainwright upgraded from Neutral to Buy rating, raising the price <a target="_blank" href="https://www.benzinga.com/quote/KYTX/analyst-ratings" rel="noreferrer noopener">target from $4 to $5</a>.
Kyverna might consider giving MG patients another dose of KYV-101 in the future, though that&#8217;s not the current plan.
For context, according to one report, ArgenX SE&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) Vyvgart costs between $300,000 and $450,000 per year, and KYV-101 would likely be priced in a similar range.
Because of that, Kapoor writes the therapy should at least offer lasting remission for a year to be considered a cost-effective and preferred option for treating MG.
Price Action: KYTX stock is up 14.9% at $2.61 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624771/qualcomm-eyes-alphawave-to-power-ai-and-data-center-growth-analyst-sees-strategic-fit" target="_blank" rel="noreferrer noopener">Qualcomm Eyes Alphawave To Power AI And Data Center Growth, Analyst Sees Strategic Fit</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Upgrades

Price Target

Analyst Ratings

ARGX

KYTX

RNAC

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Canaccord Genuity analyst Susan Anderson reiterated the Buy rating on e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) <a href="https://www.benzinga.com/quote/ELF/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $105</a>.
On May 23, the firm disclosed via social media its plan to increase prices by $1 starting August 1, attributing the decision to the current tariff environment.
According to Anderson, this development should be viewed positively, as it suggests the company&#8217;s tariff impact is &#8216;manageable&#8217; using its existing strategy while continuing to provide affordable, high-quality products.
Also Read:<a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession" target="_blank" rel="noreferrer noopener"> &#8216;Big Short&#8217; Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?</a>
The analyst also pointed out that the firm&#8217;s planned price increase is justified because their current average unit retail price of around $6.50 is significantly lower than that of their mass-market peers, who average over $9. It is also even further below prestige brands. 
She also observed that the company&#8217;s post suggests manufacturer&#8217;s suggested retail prices (MSRP) may differ by retailer.
The company&#8217;s post mentioned 75% of its U.S. product lineup will continue to be priced below $10, while a comment on the same page indicated that 50% of its products globally remain under the $10 mark.
The analyst noted that e.l.f. products tend to be priced higher in international markets like Europe compared to the U.S.
However, Anderson also cautioned that despite the near-term optimism, recent tariff-related statements from President Donald Trump have reintroduced a level of uncertainty regarding the broader outcome of the tariff situation.
With President Trump again stoking the flames of a trade war that appeared to be cooling with potential escalation against the European Union and on Apple products, tariff risk may not be in the rearview mirror just yet, she stated.
The company announced that it will hold a webcast to discuss its fourth quarter fiscal 2025 <a href="https://www.benzinga.com/pressreleases/25/05/b45530147/e-l-f-beauty-announces-earnings-release-date-for-fourth-quarter-fiscal-2025-results" target="_blank" rel="noreferrer noopener">results on Wednesday, May 28, 2025</a>.
Anderson stated that during its earnings, she anticipates the company will provide additional details on its strategy for addressing its manufacturing exposure in China.
The analyst projects the company to report quarterly adjusted EPS of 71 cents, and sales of $327.7 million.
Price Action: ELF shares are trading higher by 8.23% to $90.84 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45616623/temu-parent-pdd-does-not-mention-tariffs-impact-blames-external-environment-and-ecosystem-investments-for-profit-plunge" target="_blank" rel="noreferrer noopener">Temu Parent PDD Does Not Mention Tariffs Impact, Blames &#8216;External Environment&#8217; And &#8216;Ecosystem Investments&#8217; For Profit Plunge</a></li>
</ul>
Image by LisaChi via Shutterstock

Equities

Reiteration

Markets

e.l.f. Beauty's $1 Price Hike Seen As 'Manageable' Tariff Move: Analyst

Savara Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy for treating patients with autoimmune Pulmonary <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Alveolar Proteinosis (PAP)</a>.
Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45615282/savara-receives-refusal-to-file-rtf-letter-from-the-u-s-food-and-drug-administration-fda-for-the-b" rel="noreferrer noopener">in the lungs&#8217; alveoli</a>.
Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing.
As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange and clinical symptoms of shortness of breath, often with cough and frequent fatigue.
Also Read: <a href="https://www.benzinga.com/25/05/45621885/abbvie-highlights-cancer-trial-data-presentation-at-upcoming-asco-annual-meeting" target="_blank" rel="noreferrer noopener">AbbVie To Present Cancer Trial Data At Upcoming ASCO Event</a>
Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC).
The RTF did not result from safety concerns, and the FDA did not request or recommend additional efficacy studies.
Within 30 days, the company intends to request a Type A meeting with the Agency.
&#8220;The requested CMC data outlined in the RTF letter are currently being generated, and we look forward to meeting with the FDA to align on next steps,&#8221; said Matt Pauls, Chair and CEO, Savara. &#8220;Based on our understanding of the letter, we are confident we can thoroughly address the Agency&#8217;s request and expect to resubmit our BLA in the fourth quarter of 2025. We remain highly confident in our program for autoimmune PAP and believe that our clinical data demonstrate that MOLBREEVI improves pulmonary gas transfer and respiratory health-related quality of life in this rare disease.&#8221;
Pauls continued, &#8220;As outlined in our Annual Report, we are working to establish a redundant supply chain. Pursuant to that strategy, we remain on track to complete the technology transfer with our second-source drug substance contract manufacturer in the fall. We have completed three upstream process performance qualification (PPQ) batches, are in the process of completing our downstream PPQ campaign, and have begun our analytical comparability analysis.&#8221;
Price Action: SVRA stock is down 28.9% at $2.02 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a></li>
</ul>
Photo via Shutterstock

SVRA

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is on track to close one of its worst months ever after slashing its full-year profit outlook despite beating <a href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say">first-quarter earnings estimates. </a>
But a glimmer of hope lies ahead, as June historically stands out as the drugmaker's best month of the year.
Shares of Eli Lilly are down 19% in May, pacing for their worst monthly performance since February 2009. However, the underperformance compared to the broader market has been even more severe.
The stock has lagged the S&amp;P 500 Index by 23.8% this month — the steepest relative decline since August 2000 and the second-largest since the company went public in 1970.
<h3 class="wp-block-heading">Chart: Eli Lilly Suffered One Of Its Worst Months Ever</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png" alt="" class="wp-image-928926" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Sparked The Selloff?</h3>
The sharp move followed the company's May 1 quarterly earnings. While Lilly posted better-than-expected first-quarter results, the stock plunged 12% that day — the worst single-session drop since August 2000.
The decline was triggered by a sharp cut in the company's full-year profit forecast. Eli Lilly cited $1.57 billion in acquired in-process research and development (IPR&amp;D) charges, primarily tied to its acquisition of a cancer therapy from Scorpion Therapeutics. While sales guidance remained unchanged, full-year profit expectations were revised downward to reflect those R&amp;D costs.
For 2025, Eli Lilly projects revenue between $58 billion and $61 billion, implying a 32% year-over-year increase.
&#8220;Expect volatility, take advantage of moment of weakness, as long as there is not a new, fundamental crack in the story,&#8221; said Bank of America analyst Tim Anderson. The firm reaffirmed its 12-month price target of $1,000, suggesting a 38% upside from current levels.
<h3 class="wp-block-heading">Could June Offer Relief?</h3>
While May has battered Lilly shareholders, June has historically brought better fortune. Over the past 30 years, shares have gained an average of 2.94% during the month, according to TradingView data.
June is statistically Eli Lilly's best month, with a 67% chance of closing higher. 
Even more notable: the past five Junes have all ended in the green. The best June performance came in 2000 when the stock surged 28.1%. Only two Junes in recent history delivered double-digit losses — in 2001 and 2019, both dropping 10.6%.
There's precedent for a bounce. In 1997 and 2003, Eli Lilly dropped more than 10% in May. In both cases, shares recovered in June with gains of 3.9% and 14.1%, respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Year</th>
<th>$LLY June Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>3.00%</td>
</tr>
<tr>
<td>1996</td>
<td>0.94%</td>
</tr>
<tr>
<td>1997</td>
<td>12.65%</td>
</tr>
<tr>
<td>1998</td>
<td>3.85%</td>
</tr>
<tr>
<td>1999</td>
<td>-4.91%</td>
</tr>
<tr>
<td>2000</td>
<td>28.14%</td>
</tr>
<tr>
<td>2001</td>
<td>-10.58%</td>
</tr>
<tr>
<td>2002</td>
<td>-5.98%</td>
</tr>
<tr>
<td>2003</td>
<td>14.10%</td>
</tr>
<tr>
<td>2004</td>
<td>-6.78%</td>
</tr>
<tr>
<td>2005</td>
<td>-4.43%</td>
</tr>
<tr>
<td>2006</td>
<td>7.02%</td>
</tr>
<tr>
<td>2007</td>
<td>-2.95%</td>
</tr>
<tr>
<td>2008</td>
<td>4.90%</td>
</tr>
<tr>
<td>2009</td>
<td>0.18%</td>
</tr>
<tr>
<td>2010</td>
<td>7.98%</td>
</tr>
<tr>
<td>2011</td>
<td>-0.66%</td>
</tr>
<tr>
<td>2012</td>
<td>0.80%</td>
</tr>
<tr>
<td>2013</td>
<td>-6.19%</td>
</tr>
<tr>
<td>2014</td>
<td>1.92%</td>
</tr>
<tr>
<td>2015</td>
<td>8.09%</td>
</tr>
<tr>
<td>2016</td>
<td>4.86%</td>
</tr>
<tr>
<td>2017</td>
<td>2.94%</td>
</tr>
<tr>
<td>2018</td>
<td>-0.14%</td>
</tr>
<tr>
<td>2019</td>
<td>-10.60%</td>
</tr>
<tr>
<td>2020</td>
<td>5.40%</td>
</tr>
<tr>
<td>2021</td>
<td>12.41%</td>
</tr>
<tr>
<td>2022</td>
<td>12.92%</td>
</tr>
<tr>
<td>2023</td>
<td>2.56%</td>
</tr>
<tr>
<td>2024</td>
<td>6.67%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Average</td>
<td>2.94%</td>
</tr>
</tfoot>
</table>
</figure>
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">Goldman Sachs Taps This Defense Stock As Prime Beneficiary Of Trump&#8217;s $175B Golden Dome</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?

Bank of America Securities analyst Sara Senatore explained that while the restaurant industry may seem simple due to its familiarity with consumers, investing in restaurant stocks remains complex, <a href="https://www.benzinga.com/general/restaurants/25/05/45417777/lobster-life-sibling-entrepreneurs-see-trade-turmoil-as-a-business-edge" target="_blank" rel="noreferrer noopener">given the wide performance variation within the sector.</a>
According to Senatore, in today&#8217;s value-conscious environment, the restaurants seeing success are those offering standout products and experiences across multiple dimensions.
This consistent execution has allowed leading quick-service pizza chains to expand market share, and she highlights that Domino&#8217;s Pizza Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is positioned to continue outperforming, backed by its partnerships with delivery platforms like DoorDash, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)
and Uber Technologies, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) UberEats, value-oriented menu strategies, and technological strength. The analyst reiterated the Buy rating on Domino&#8217;s, <a target="_blank" href="https://www.benzinga.com/quote/DPZ/analyst-ratings" rel="noreferrer noopener">with a price forecast of $549.</a>
Also Read:<a target="_blank" href="https://www.benzinga.com/general/restaurants/25/05/45400599/only-reasonable-profits-jdcom-takes-aim-at-global-food-delivery-economics-with-zero-commission-modelrevives-founders-035-principle" rel="noreferrer noopener"> &#8216;Only Reasonable Profits:&#8217; JD.com Takes Aim At Global Food Delivery Economics With Zero-Commission Model—Revives Founder&#8217;s &#8216;$0.35 Principle&#8217;</a>
The analyst expressed optimism about Papa John&#8217;s International, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>), anticipating an improved earnings profile after the company&#8217;s planned investments in 2025. Senatore reiterated the Buy rating, <a target="_blank" href="https://www.benzinga.com/quote/PZZA/analyst-ratings" rel="noreferrer noopener">with a price forecast of $52.</a>
Senatore noted that Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), the parent company of Pizza Hut, has maintained stable returns on assets compared to the broader market, and she views the company&#8217;s historical performance range as a solid basis for future estimates. The analyst reiterated the Neutral rating <a target="_blank" href="https://www.benzinga.com/quote/YUM/analyst-ratings" rel="noreferrer noopener">with a price forecast of $159.</a>
Senatore highlighted market share dynamics among these top three pizza chains, noting that Domino&#8217;s has continued to gain share, Papa Johns has maintained its position, while Pizza Hut has seen a decline in share.
Out of the Pizza focus, the analyst sees Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) &#8216;s same-store sales growth could be slower than expected if macro headwinds pressure restaurant consumption or sales-driving initiatives fail to resonate with customers. Senatore reiterated the company&#8217;s Underperform rating, with a price forecast of $7.
Senatore noted that McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) could deliver better-than-expected margins and returns if it slows down its investment pace or uncovers unanticipated cost savings.
She also suggested that if investor sentiment turns more risk-averse, McDonald&#8217;s defensive profile could become increasingly appealing in the current market environment. The analyst reiterated the Neutral rating on McDonald&#8217;s with a price forecast of $327.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45328334/steak-n-shake-goes-steaktoshi-embraces-bitcoin-maga-culture-tesla-fanbase" target="_blank" rel="noreferrer noopener">Steak &#8216;N Shake Goes &#8216;Steaktoshi&#8217;: Embraces Bitcoin, MAGA Culture, Tesla Fanbase</a></li>
</ul>
Image: Shutterstock

BLMN

DASH

PZZA

UBER

Pizza Power Play: Analyst Says Domino's Gains Share, Papa Johns Holds Steady, Pizza Hut Loses Ground

WIIM

ATXG

BGLC

BlackSky Technology Inc. Class A Common Stock

BKSY

BYRN

CAPT

CMCO

EVEX

FTAI

IESC

INOD

KTOS

LUNR

NCRA

NVVE

ONEG

RKLB

ROMA

SATL

SHIM

TPIC

ULBI

ULCC

VATE

Shares of companies within the broader industrial sector are trading higher, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.

APTV

ARHS

BALY

BGFV

BYON

CAKE

ESCA

EXPE

FIVE

GPRO

GROV

IRBT

JZXN

LVWR

MBLY

NWTN

PLAY

PLBY

SBUX

SERV

SHAK

SLDP

TXRH

ULTA

VMAR

XPOF

YSXT

Shares of companies within the broader consumer discretionary sector are trading higher, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.

DECK

ROST

Shares of apparel companies are trading higher, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45618809/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics" rel="noreferrer noopener">studied for pain</a>.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say" rel="noreferrer noopener">Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say</a>
&#8220;The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive,&#8221; said Mark Mintun, Lilly group vice president of Neuroscience Research and Development. &#8220;Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies.&#8221;
Under the terms of the agreement, Lilly will acquire SiteOne, and SiteOne shareholders could receive up to $1 billion in cash, including an upfront payment and subsequent payments upon achieving certain regulatory and commercial milestones.
Earlier in May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with&nbsp;Rznomics Inc.,&nbsp;a&nbsp;South Korea-based biopharmaceutical company specializing&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" rel="noreferrer noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
If Lilly exercises all available options under the agreement, the total deal value could reach more than&nbsp;$1.3 billion, and separate royalties on product sales. The upfront payment was not disclosed.&nbsp;
Price Action: LLY stock is up 1.7% at $726.14 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45626048/why-marvells-ai-revenue-could-top-4-billion-by-2025-analyst-explains" target="_blank" rel="noreferrer noopener">Why Marvell&#8217;s AI Revenue Could Top $4 Billion By 2025, Analyst Explains</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

All eyes turn to NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and the company's AI dominance, new products and questions for the China market when the company reports first-quarter financial results Wednesday <a href="https://www.benzinga.com/earnings">after market close.</a>
Here are the analyst earnings estimates, what experts are saying ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Nvidia to report first-quarter revenue of $43.54 billion, up from $26.04 billion in last year's first quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"> from Benzinga Pro.</a>
The revenue estimate would be a company record, beating the $39.33 billion reported in the fourth quarter.
Nvidia has beaten analyst estimates for revenue in 10 straight quarters.
Analysts expect Nvidia to report first-quarter earnings per share of 88 cents, up from 61 cents per share in last year's first quarter. The company has beaten analyst estimates for earnings per share in nine straight quarters.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45608914/nvidia-earnings-on-deck-can-ai-darling-beat-the-streets-high-bar-amid-china-headwinds">Nvidia Earnings On Deck: Can AI Darling Beat The Street&#8217;s High Bar Amid China Headwinds?</a>
 What Experts Are Saying: Nvidia stock could be flat to down heading into the earnings report due to macro uncertainty and a ban on the H20 AI chip in China, Piper Sandler analyst Harsh Kumar said in a new investor note ahead of Q1 results.
"The new re-spun China chip will likely be commercialized in the late part of the July quarter, which could also impact July's guide," he said, reiterating an Overweight rating and $150 price target on Nvidia.
Kumar said most of the factors that could hurt Nvidia's first quarter are outside the company's control. The analyst sees a strong back half of the year coming for Nvidia with macro forces improving.
"We advise investors to weather the uncertainty and stay long the stock as this is likely largely the last wave of negative news for NVDA this year."
Freedom Capital Markets Chief Global Strategist Jay Woods said there are three main things investors will be watching and listening for in Nvidia's report.
Woods called Nvidia "the poster child for all that is AI."
Woods said the three things that will be most watched are sales of the Blackwell chip, the export restrictions on China, and guidance.
"Government restrictions have limited Nvidia's ability to export certain AI chips, like the H20, to China, potentially affecting revenue," Woods said in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
The market strategist said investors will be looking at Nvidia's guidance to see how the giant can navigate this setback, including potential new, compliant chip variants for the Chinese market.
After a history of raising projections for future earnings, Woods questions if the trend can continue given the growth concerns, global competition, and inflation concerns Nvidia faces.
Here are other recent<a href="https://www.benzinga.com/quote/NVDA/analyst-ratings"> analyst ratings on Nvidia</a> and their price targets:
<ul class="wp-block-list">
<li>Wedbush: Reiterated Outperform rating, $175 price target</li>
<li>Bank of America: Maintained Buy rating, raised price target from $150 to $160</li>
<li>UBS: Maintained Buy rating, lowered price target from $180 to $175</li>
</ul>
Key Items to Watch: Nvidia has shown huge year-over-year and quarter-over-quarter growth in recent years. With another record quarter predicted by analysts, guidance will become increasingly important.
The company posted a 12% quarter-over-quarter sales increase in<a href="https://www.benzinga.com/news/earnings/25/02/43991607/nvidia-q4-earnings-highlights-revenue-beat-eps-beat-demand-for-blackwell-is-amazing"> the fourth quarter</a>, with sales up 78% year-over-year. Given the tougher comps, triple-digit growth is likely gone, and eventually, this growth forecast could continue to fall.
Data Center segment revenue hit another record in the fourth quarter, with $35.6 billion, up 93% year over year.
The fourth quarter saw Data Center carry the company with Gaming &amp; AI PC segment revenue down 11% year-over-year and Professional Visualization revenue up 10% year-over-year. The company's automotive segment saw strong overall year-over-year growth of 103% in the quarter, but it was the smallest segment by revenue ($570 million).
Another area to watch could be any talk about competition. Chip competitor AMD <a href="https://www.benzinga.com/25/05/45550527/amd-takes-on-nvidia-stock-with-direct-shot-at-gpus-reviewer-says-rx-9060-could-hit-the-bullseye">recently unveiled the</a> Radeon RX 9060 XT and Radeon AI Pro R9700 graphics cards. The new graphics cards will bring AI capabilities to workstations and gamers worldwide and increase AMD's competition with Nvidia.
Tech reviewer Tom&#8217;s Guide&nbsp;<a href="https://www.tomsguide.com/computing/gpus/amds-radeon-rx-9060-xt-is-a-direct-shot-at-nvidias-rtx-5060-heres-why-i-think-it-will-hit-the-bullseye" target="_blank" rel="noreferrer noopener">said&nbsp;</a>the RX 9060 XT's release is a &#8220;direct shot&#8221; at Nvidia&#8217;s RTX 5060. The reviewer believes AMD&#8217;s product could &#8220;hit the bullseye&#8221; in the competitive race.
While Nvidia likely won't comment on the competition, it could provide keywords and highlight how its products are the best on the market.
Another area to watch with Nvidia's stock report will be if other peer companies go higher or lower on the news. Nvidia's post-earnings move will also have a large impact on several of the most-watched stock market indexes and ETFs.
Nvidia is the second-largest holding of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), with a 6.5% weighting. A sharp decline in Nvidia's stock price due to guidance could send the overall S&amp;P 500 and ETFs lower on the week.
Nvidia is the second-largest holding of the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), with an 8.3% weighting.
The stock is also a member of the Dow Jones Industrial Average, but due to the index being price-weighted, it makes up a smaller percentage and holding in ETFs, like being the 23rd largest holding in the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) and 1.9% of assets.
NVDA Price Action: Nvidia stock was up 3.2% to $135.44 on Tuesday, versus a 52-week trading range of $86.63 to $153.13. However, it is down 2.2% year-to-date in 2025, while shares have increased over 18% in the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/education/25/05/45504571/does-jensen-huang-check-nvidia-stock-price-daily-2">Does Jensen Huang Check Nvidia Stock Price Daily?</a></li>
</ul>
Photo: Shutterstock

Previews

Tech

SPDR Dow Jones Industrial Average ETF Trust

NVDA

NVIDIA Q1 Earnings Preview: Analyst Cautions On Macro Uncertainty, China Restrictions - 'Stay Long The Stock'

Payments startup Airwallex<a href="https://www.airwallex.com/newsroom/airwallex-raises-usd300-million-at-a-usd6-2-billion-valuation-to-build-the-future-of-global-banking"> announced</a> Wednesday that it secured a new $300 million funding round, pushing its valuation to $6.2 billion.
Founded in 2015, Airwallex has grown into a global player by helping businesses send, receive, and manage international payments at scale, <a href="https://www.reuters.com/business/finance/fintech-airwallex-valued-over-6-billion-latest-funding-round-2025-05-21/">Reuters</a> reports. With a network spanning more than 150 countries, the company now reports over $1.2 billion in total funding, with investors of the latest round including major names like DST Global, Square Peg, Lone Pine Capital, and Blackbird.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
<h2 class="wp-block-heading">Strategic Growth Amid Industry Slowdown</h2>
While fintech startups exploded in valuation post-pandemic, many are now facing investor fatigue. According to Reuters, persistently high interest rates, recession concerns, and geopolitical volatility have forced many firms to delay fundraising or accept lower terms.
Airwallex has bucked that trend since its 11% increase in valuation from the previous round in 2022 is a signal of both operational strength and investor confidence. The company now counts industry giants like Shein, Qantas, and Xero among its client base, Reuters says.
CEO Jack Zhang told Reuters that more than 70% of the company's net revenue now comes from online payment processing and spend management, rather than just cross-border infrastructure.
The diversification strategy appears to be paying off. Zhang emphasized in the company&#8217;s announcement that Airwallex is no longer just a cross-border payments solution, but a broader financial operating system for modern businesses.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
&#8220;The global financial system wasn't built for today's borderless economy,&#8221; Zhang said. &#8220;Too many businesses are held back by legacy infrastructure that's slow, costly, and fragmented. At Airwallex, we're building a new foundation for the global economy – one that's fast, seamless, and built for scale. This investment marks a major milestone in our journey to redefine global banking, and to empower businesses everywhere to grow without limits.&#8221;
<h2 class="wp-block-heading">Expanding Global Footprint With U.S. And Asia Focus</h2>
Airwallex is also doubling down on global expansion. The company said it opened its U.S. headquarters in San Francisco last year and recently opened new offices in New York, Toronto, and Paris. According to Reuters, the startup is joining other payment providers competing with major players like JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>).
In addition to its growing presence in North America, Airwallex is targeting Japan, South Korea, and Latin America as core areas for future growth. With a global headquarters now based in Singapore, the company is positioning itself as a truly borderless platform for modern business finance, Reuters says.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Riding A New Wave Of Fintech Infrastructure</h2>
Airwallex said it developed a proprietary global infrastructure designed to modernize how businesses move money across borders. By building direct connections to local clearing systems and card networks, the company has created a faster, more efficient alternative to traditional banking rails. Most of the company&#8217;s transactions are completed within hours, with a majority processed instantly.
With tools that span global business accounts, FX, spend management, and embedded finance APIs, Airwallex is positioning itself as the operating system for modern businesses. With the new funding, Airwallex said in its funding announcement that it is now preparing for its next phase: deeper integration, bigger partnerships, and an even broader global footprint.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
Image: Shutterstock

Airwallex Raises $300M As It Expands In U.S. And Latin America, Now Valued At $6.2B With Clients Like Shein And Xero

<a href="https://nypost.com/2025/05/27/us-news/donald-trump-jr-hosting-nyc-investor-event-for-amazon-of-guns-aims-to-ring-nyse-bell-for-pew-in-june/" title="https://nypost.com/2025/05/27/us-news/donald-trump-jr-hosting-nyc-investor-event-for-amazon-of-guns-aims-to-ring-nyse-bell-for-pew-in-june/">https://nypost.com/2025/05/27/us-news/donald-trump-jr-hosting-nyc-investor-event-for-amazon-of-guns-aims-to-ring-nyse-bell-for-pew-in-june/</a>

IPOs

SWBI

'Donald Trump Jr. Hosting NYC Investor Event For 'Amazon Of Guns' — Aims To Ring NYSE Bell For 'PEW' In June' - NY Post

NCLH

Shares of cruise stocks are trading higher, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July. The industry may also be experiencing a rise due to a surge in travel during Memorial Day weekend.

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Shares of hotel companies are trading higher, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July. The industry may also be experiencing a rise due to a surge in travel during Memorial Day weekend.

Press Releases

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

Comments

KalVista Pharma

KalVista Pharma (KALV) Opzioni

KalVista Pharma (NASDAQ:KALV) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO